DNA methylation as a marker of response in rheumatoid arthritis

Nisha Nair, Anthony G. Wilson, Anne Barton

Research output: Contribution to journalReview articlepeer-review

130 Downloads (Pure)

Abstract

Rheumatoid arthritis (RA) is a complex disease affecting approximately 0.5-1% of the population. While there are effective biologic therapies, in up to 40% of patients, disease activity remains inadequately controlled. Therefore, identifying factors that predict, prior to the initiation of therapy, which patients are likely to respond best to which treatment is a research priority and DNA methylation is increasingly being explored as a potential theranostic biomarker. DNA methylation is thought to play a role in RA disease pathogenesis and in mediating the relationship between genetic variants and patient outcomes. The role of DNA methylation has been most extensively explored in cancer medicine, where it has been shown to be predictive of treatment response. Studies in RA, however, are in their infancy and, while showing promise, further investigation in well-powered studies is warranted.

Original languageEnglish
Pages (from-to)1323-1332
Number of pages10
JournalPharmacogenomics
Volume18
Issue number14
Early online date24 Aug 2017
DOIs
Publication statusPublished - 2017

Keywords

  • DNA methylation
  • rheumatoid arthritis
  • treatment response

Fingerprint

Dive into the research topics of 'DNA methylation as a marker of response in rheumatoid arthritis'. Together they form a unique fingerprint.

Cite this